Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Institut de Cancérologie de Lorraine
Sun Yat-sen University
Sixth Affiliated Hospital, Sun Yat-sen University
Jules Bordet Institute
Erasmus Medical Center
Institut Bergonié
Sun Yat-sen University
GERCOR - Multidisciplinary Oncology Cooperative Group
Nizhny Novgorod Regional Clinical Oncology Center
Memorial Sloan Kettering Cancer Center
Changhai Hospital
Sichuan Cancer Hospital and Research Institute
Gritstone bio, Inc.
Nanchong Central Hospital
Krankenhaus Nordwest
Sun Yat-sen University
Larissa University Hospital
Zhejiang Cancer Hospital
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
University of Nebraska
Eastern Cooperative Oncology Group
Yonsei University
Sun Yat-sen University
Sun Yat-sen University
The Catholic University of Korea
Wake Forest University Health Sciences
ChineseAMS
UNICANCER
State Scientific Centre of Coloproctology, Russian Federation
St. Petersburg State Pavlov Medical University
Swiss Cancer Institute
UNICANCER
The First Affiliated Hospital of Dalian Medical University
University of Zurich
Royal Marsden NHS Foundation Trust
Case Comprehensive Cancer Center
University of Sao Paulo General Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Peking University
West China Hospital
Roswell Park Cancer Institute
University of Washington
City of Hope Medical Center
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
Harbin Medical University
UNICANCER
Medical Research Council
Sixth Affiliated Hospital, Sun Yat-sen University